NCT00318812 is a Phase 2/Phase 3 clinical trial of Heme Iron Polypeptide (Proferrin) in Anemia, sponsored by Ottawa Hospital Research Institute.

Who is sponsoring NCT00318812?

NCT00318812 is sponsored by Ottawa Hospital Research Institute.

What drugs are being tested in NCT00318812?

Interventions in NCT00318812: Heme Iron Polypeptide (Proferrin), Iron sucrose (Venofer).

What condition does NCT00318812 study?

NCT00318812 studies Anemia, Renal Failure.

Is NCT00318812 still recruiting?

NCT00318812 is currently completed. Last updated 5 April 2016.

Are results published for NCT00318812?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2016-04-05 · How we verify

NCT00318812

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Heme Iron Polypeptide for the Treatment of Iron Deficiency Anemia in Pre-Dialysis Patients: A Pilot Randomized Controlled Study

Completed Phase 2/Phase 3 Results posted Last updated 5 April 2016

What this trial tests

Phase 2/Phase 3 trial testing Heme Iron Polypeptide (Proferrin) in Anemia in 55 participants. Completed in 1 December 2011.

Timeline

1 May 2007

Primary endpoint
1 December 2011

1 December 2011

Quick facts

Lead sponsor	Ottawa Hospital Research Institute
Phase	Phase 2/Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	55
Start date	1 May 2007
Primary completion	1 December 2011
Estimated completion	1 December 2011
Sites	1 location across Canada

Drugs / interventions tested

Heme Iron Polypeptide (Proferrin) — full drug profile →
Iron sucrose (Venofer) — full drug profile →

Conditions studied

Anemia — all drugs for Anemia →
Renal Failure — all drugs for Renal Failure →

Sponsor

Ottawa Hospital Research Institute

Who can join

18 and older, any sex, with Anemia or Renal Failure. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Hemoglobin Concentration at 6 Months
Time frame: 6 months

Sponsor's own description

The purpose of this study is to determine if oral Heme Iron Polypeptide is as effective as intravenous (IV) iron sucrose in the treatment of iron-deficiency anemia for patients with chronic kidney disease.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Heme iron polypeptide for the treatment of iron deficiency anemia in non-dialysis chronic kidney disease patients: a randomized controlled trial.
Nagaraju SP, Cohn A, Akbari A, Davis JL, et al · · 2013 · cited 28× · PMID 23514036 · DOI 10.1186/1471-2369-14-64

Verify or expand the search:

Other recruiting trials for Anemia

Currently open trials in the same condition.

NCT07422480 — A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myel · Phase 3 · recruiting
NCT06968936 — Long-term Outcomes Sub-Study of Preoperative Combined Iron Therapy · NA · recruiting
NCT07328191 — Quality of Life-Guided Transfusion in Refractory MDS or AML · NA · recruiting
NCT07315295 — Maximizing the Benefits of Iron in Ready-to-Use Therapeutic Foods for Malnourished Children in Kenya · NA · recruiting
NCT07400796 — Assessing Health System Readiness for Scaling Antenatal MMS in Cambodia · recruiting

Other Ottawa Hospital Research Institute trials

Trials by the same sponsor.

NCT07464080 — Advanced Brain Imaging-TKA (fMRI-TKA) · NA · recruiting
NCT07171567 — Vacuum Therapy for the Treatment of Penile Numbness/Sensory Changes · EARLY_PHASE1 · recruiting
NCT07058025 — Mesenchymal Stromal Cell Therapy to Prevent Bronchopulmonary Dysplasia in Extreme Preterm Infants · Phase 2 · not yet recruiting
NCT07177833 — Title Fractioned CO2 Laser in the Treatment of Chronic Phase Peyronie's Disease · Phase 1 · recruiting
NCT06929767 — Do Blood Tests Help to Decide Which Patients With Flares of Chronic Obstructive Pulmonary Disease (COPD) Need Antibiotic · Phase 4 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00318812 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ottawa Hospital Research Institute
Last refreshed: 5 April 2016

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00318812.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing